TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17208954

Group type: EXPERIMENTAL
Intervention: 3-year smoking prevention programme (14 information lessons about smoking and refusal skills training, integrated into the standard curriculum)
Number of subjects: 1821

Group type: COMPARATOR
Intervention: Standard health education curriculum (control group)
Number of subjects: 1821
Study: 14985932

Group type: EXPERIMENTAL
Intervention: 10 mg zolpidem
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 5 mg zolpidem
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 12488649

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: CPAP placebo
Number of subjects: 41
Study: 10360287

Group type: EXPERIMENTAL
Intervention: Topical aqueous suppressants
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (no topical aqueous suppressants)
Number of subjects: 41
Study: 7661062

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg loading dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin 500 mg loading dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg loading dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin 40/40 mg combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different combinations of aspirin doses
Number of subjects: 0
Study: 2194770

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1-0.15 mg/kg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Diazepam (0.2-0.4 mg/kg)
Number of subjects: 41
Study: 498700

Group type: EXPERIMENTAL
Intervention: Intravenous verapamil
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 28
Study: 31793991

Group type: EXPERIMENTAL
Intervention: Presatovir 200 mg
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Presatovir 200 mg (in lymphopenic patients)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo (in lymphopenic patients)
Number of subjects: 189
Study: 30992034

Group type: EXPERIMENTAL
Intervention: Deferred clamping (clamping after at least 2 min)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Immediate clamping (clamping within 20 s)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Both groups (deferred and immediate clamping)
Number of subjects: 261
Study: 27836866

Group type: EXPERIMENTAL
Intervention: sipuleucel‐T followed by ADT (started 2 weeks after sipuleucel‐T completion)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: sipuleucel‐T followed by ADT
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: sipuleucel‐T with ADT
Number of subjects: 68
Study: 25861467

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Obese T2D subjects
Number of subjects: 0
Study: 23993706

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (0.5 mg/kg BW daily) for 2 weeks
Number of subjects: 146
Study: 22290033

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Drug therapy (fluoxetine)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Combination of CBT and fluoxetine (CBT+fluoxetine)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: All treatments combined
Number of subjects: 122
Study: 19264245

Group type: EXPERIMENTAL
Intervention: Atrial pacing (at 70 beats/min)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Minimal ventricular pacing (at 40 beats/min)
Number of subjects: 600
Study: 17447516

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 0
Study: 15311169

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower doses of beta-blockers
Number of subjects: 0
Study: 11323149

Group type: EXPERIMENTAL
Intervention: 100 mg imipramine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 125 mg codeine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9011574

Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (500 microg/min)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (matched controls, n=13)
Number of subjects: 13
Study: 8225629

Group type: EXPERIMENTAL
Intervention: 1% clindamycin hydrochloride gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 20
Study: 2952095

Group type: EXPERIMENTAL
Intervention: Amantadine (300 mg/day, t.i.d.)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 29100135

Group type: EXPERIMENTAL
Intervention: Marijuana use
Number of subjects: 307
Study: 28095573

Group type: EXPERIMENTAL
Intervention: SB204 2% twice daily
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: SB204 4% once daily
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: SB204 4% twice daily
Number of subjects: 213

Group type: COMPARATOR
Intervention: Vehicle once daily
Number of subjects: 213

Group type: COMPARATOR
Intervention: Vehicle twice daily
Number of subjects: 213
Study: 23999592

Group type: EXPERIMENTAL
Intervention: Endoscopic myringoplasty
Number of subjects: 60

Group type: COMPARATOR
Intervention: Microscopic myringoplasty
Number of subjects: 60
Study: 23252284

Group type: EXPERIMENTAL
Intervention: iptakalim
Number of subjects: 110

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 110
Study: 19336536

Group type: EXPERIMENTAL
Intervention: Esmolol + Enoximone
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study: 17846933

Group type: EXPERIMENTAL
Intervention: Movina (St John's Wort product, 300 mg Hypericum perforatum, two tablets daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (commercially available multivitamin tablet, Vitamineral)
Number of subjects: 24
Study: 15151614

Group type: EXPERIMENTAL
Intervention: LAT (lansoprazole 30 mg b.d., amoxycillin 1000 mg b.d., tinidazole 500 mg b.d.)
Number of subjects: 146

Group type: COMPARATOR
Intervention: LAC (lansoprazole 30 mg b.d., amoxycillin 1000 mg b.d., clarithromycin 500 mg b.d.)
Number of subjects: 146
Study: 12236273

Group type: EXPERIMENTAL
Intervention: Telephone call from the practice receptionist offering an appointment for influenza immunisation
Number of subjects: 1820

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 1820
Study: 9841945

Group type: EXPERIMENTAL
Intervention: Cotton pledge soaked in saline (middle nasal meatus stimulation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cotton pledge soaked in 5% cocaine solution (middle nasal meatus stimulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cotton pledge soaked in saline (control group, inferior nasal concha stimulation)
Number of subjects: 0
Study: 7986255

Group type: EXPERIMENTAL
Intervention: 800 mg cyclandelate
Number of subjects: 24
Study: 2545437

Group type: EXPERIMENTAL
Intervention: Reduced phytate bran
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Standard bran
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Rice Krispies (low phytate, low fibre cereal)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Standard bran with histidine
Number of subjects: 3
Study: 6326785

Group type: EXPERIMENTAL
Intervention: Edrophonium
Number of subjects: 21

Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 21
Study: 31942818

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hand-Arm Bimanual Intensive Therapy (HABIT)
Number of subjects: 20
Study: 30948610

Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga (SKY) breathing meditation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 0
Study: 27611301

Group type: EXPERIMENTAL
Intervention: rTMS treatment (10 sessions over the bilateral dorsolateral prefrontal cortex)
Number of subjects: 14
Study: 26169948

Group type: EXPERIMENTAL
Intervention: Feedback (FB) about patients' progress using the OQ®‐Analyst system
Number of subjects: 259

Group type: COMPARATOR
Intervention: No feedback (NFB)
Number of subjects: 259
Study: 25108889

Group type: EXPERIMENTAL
Intervention: Screening (PSA testing)
Number of subjects: 13515

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 13515
Study: 22412073

Group type: EXPERIMENTAL
Intervention: Behavioral intervention promoting weight loss and hypertension self-management using eHealth components (tailored behavior change goals, self-monitoring, skills training, 18 telephone counseling calls, primary care provider endorsement, 12 optional group support sessions, links with community resources)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 365
Study: 20956906

Group type: EXPERIMENTAL
Intervention: Transurethral resection of prostate (TURP)
Number of subjects: 68
Study: 17386092

Group type: EXPERIMENTAL
Intervention: 6 grams/day concentrated oat beta-glucan
Number of subjects: 75

Group type: COMPARATOR
Intervention: 6 grams/day dextrose (control)
Number of subjects: 75
Study: 16304291

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg qd)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Levofloxacin (500 mg qd)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 394

Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 394
Study: 12138952

Group type: EXPERIMENTAL
Intervention: AHA step 1 diet for 8 to 10 weeks
Number of subjects: 4257

Group type: COMPARATOR
Intervention: Labile LDL-C levels (LI and LD groups)
Number of subjects: 4257

Group type: COMPARATOR
Intervention: Stable LDL-C levels (LN group)
Number of subjects: 4257
Study: 9794155

Group type: EXPERIMENTAL
Intervention: Mono‐Tildiem LP 300 (300 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Adizem XL (300 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cardizem (300 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dilacor (240 mg)
Number of subjects: 16
Study: 8605713

Group type: EXPERIMENTAL
Intervention: 14 gauge needles at QB 500 cc/min
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 17 gauge needles at QB 500 cc/min
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 14 gauge needles at QB 200 cc/min
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 17 gauge needles at QB 200 cc/min
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 15 gauge needles
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 14 gauge needles
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 16 gauge needles
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 17 gauge needles
Number of subjects: 21
Study: 2671072

Group type: EXPERIMENTAL
Intervention: 10-week supplemental behavioral skills training course (n = 70)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (n = 60)
Number of subjects: 130
Study: 322834

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 21

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 21
Study: 31583805

Group type: EXPERIMENTAL
Intervention: Responsive treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 50
Study: 30864970

Group type: EXPERIMENTAL
Intervention: Merino wool clothing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard clothing
Number of subjects: 0
Study: 28235526

Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 μg/min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ephedrine 5 mg/min
Number of subjects: 40
Study: 26032587

Group type: EXPERIMENTAL
Intervention: Dihydromyricetin (150 mg, two capsules twice daily for three months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (150 mg, two capsules twice daily for three months)
Number of subjects: 60
Study: 22891750

Group type: EXPERIMENTAL
Intervention: Twin Force Bite Corrector (TFBC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (nontreated patients)
Number of subjects: 43
Study: 21462332

Group type: COMPARATOR
Intervention: Isolated coumarin in a capsule (reference)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cinnamon in capsules
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cinnamon tea
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cinnamon in rice pudding
Number of subjects: 24
Study: 18707693

Group type: EXPERIMENTAL
Intervention: Duloxetine (switch method: direct switch or start-taper switch)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duloxetine (start-taper switch)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duloxetine (overall treatment)
Number of subjects: 0
Study: 17580028

Group type: EXPERIMENTAL
Intervention: Protease‐modulating dressing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standardized protocol for good wound care (Control)
Number of subjects: 40
Study: 15147430

Group type: EXPERIMENTAL
Intervention: SRL‐ST (sirolimus-steroid)
Number of subjects: 430

Group type: COMPARATOR
Intervention: CsA-Withdrawal (SRL‐ST)
Number of subjects: 430
Study: 11199944

Group type: EXPERIMENTAL
Intervention: Ziprasidone 160 mg/day
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Ziprasidone 120 mg/day
Number of subjects: 115

Group type: COMPARATOR
Intervention: Ziprasidone 40 mg/day
Number of subjects: 115

Group type: COMPARATOR
Intervention: Ziprasidone 80 mg/day
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 9849281

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 180
Study: 8291732

Group type: EXPERIMENTAL
Intervention: Sufentanil-lorazepam
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Halothane and Isoflurane
Number of subjects: 21
Study: 3188847

Group type: EXPERIMENTAL
Intervention: Silver-palladium alloy Albacast
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low-gold alloy Midas
Number of subjects: 23

Group type: COMPARATOR
Intervention: High-gold type-3 alloy JS C
Number of subjects: 23
Study: 31488144

Group type: EXPERIMENTAL
Intervention: Service transformation along the key foci (early identification, rapid access, appropriate care, elimination of age-based transitions, engagement of youth and families)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Service transformation along the key foci
Number of subjects: 14
Study: 28784701

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) supplementation (10 billion CFU and 225 mg of inulin)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (325 mg of inulin alone)
Number of subjects: 184
Study: 26270573

Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet
Number of subjects: 52

Group type: COMPARATOR
Intervention: Low-fat diet (control group)
Number of subjects: 52
Study: 24084626

Group type: EXPERIMENTAL
Intervention: Intralesional abciximab
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Number of subjects: 452
Study: 22117995

Group type: EXPERIMENTAL
Intervention: Dexketoprofen added to lidocaine in IVRA
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 45
Study: 20126911

Group type: EXPERIMENTAL
Intervention: SRP with tetracycline‐loaded absorbent membrane
Number of subjects: 24

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 24
Study: 16565636

Group type: EXPERIMENTAL
Intervention: Enhanced depression treatment
Number of subjects: 198

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 198
Study: 15169741

Group type: EXPERIMENTAL
Intervention: PGE1 20 ng kg(‐1) min(‐1) i.v. during anaesthesia
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no PGE1)
Number of subjects: 14
Study: 10943869

Group type: EXPERIMENTAL
Intervention: 20 mg/day intravenous administration of anti‐IL‐10 monoclonal antibody (B‐N10) for 21 consecutive days
Number of subjects: 6
Study: 9077368

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (7 sessions during weeks 10 and 11)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no acupuncture treatment)
Number of subjects: 33
Study: 8336991

Group type: EXPERIMENTAL
Intervention: Imagery techniques (matched intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensory focusing (mismatched intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 0
Study: 3944815

Group type: EXPERIMENTAL
Intervention: Atropine 1.2 mg
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Atropine 1.8 mg
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.6 mg
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.9 mg
Number of subjects: 115
Study: 29798500

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized dermatophagoides farinae drops for 12 months
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no SLIT)
Number of subjects: 92
Study: 27348641

Group type: EXPERIMENTAL
Intervention: Arnica ointment 10%
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 136
Study: 25009971

Group type: EXPERIMENTAL
Intervention: Aerobic Training Group (ATG, n=19)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Mixed Aerobic and Resistance Training Group (MTG, n=20)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control Group (n=20)
Number of subjects: 59
Study: 22363015

Group type: EXPERIMENTAL
Intervention: Long-term multifactor cardiovascular disease (CVD) risk reduction program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 20878045

Group type: EXPERIMENTAL
Intervention: 3-month exercise programme (n = 56)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual care (n = 49)
Number of subjects: 105
Study: 18674411

Group type: EXPERIMENTAL
Intervention: Rivastigmine capsules (3-12 mg/day)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Rivastigmine capsules (3-12 mg/day) in older patients (>=75 years old)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Rivastigmine capsules (3-12 mg/day) in younger patients (less than 75 years old)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Rivastigmine capsules (3-12 mg/day) in patients with medial temporal atrophy
Number of subjects: 710
Study: 16130427

Group type: EXPERIMENTAL
Intervention: thiotropium bromide, 18 microg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: ipratropium bromide, 160 microg/day
Number of subjects: 20
Study: 14650953

Group type: COMPARATOR
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative chemotherapy
Number of subjects: 0
Study: 10665980

Group type: EXPERIMENTAL
Intervention: Artemisinin and its derivatives
Number of subjects: 0
Study: 9258016

Group type: EXPERIMENTAL
Intervention: Clinical pathways and dedicated vascular wing implementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 1510255

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg of metoclopramide
Number of subjects: 102

Group type: COMPARATOR
Intervention: Saline solution placebo
Number of subjects: 102
Study: 6207158

Group type: EXPERIMENTAL
Intervention: Short course of ARA‐AMP (4 weeks)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Long course of ARA‐AMP (7 to 12 weeks)
Number of subjects: 31
Study: 30693979

Group type: EXPERIMENTAL
Intervention: Fe‐Gly (60 mg Fe/kg)
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Fe‐Gly (60, 80 mg Fe/kg)
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Fe‐Gly (40 mg Fe/kg)
Number of subjects: 810

Group type: COMPARATOR
Intervention: FeSO4 (60 mg Fe/kg)
Number of subjects: 810
Study: 30227360

Group type: EXPERIMENTAL
Intervention: Public participation process and tailored traffic enforcement program
Number of subjects: 12236

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12236
Study: 27456147

Group type: EXPERIMENTAL
Intervention: Tunneled subcutaneous perineural catheter
Number of subjects: 338

Group type: COMPARATOR
Intervention: Control group with adhesive strips
Number of subjects: 338
Study: 24268590

Group type: EXPERIMENTAL
Intervention: Oseltamivir (598 participants)
Number of subjects: 1190

Group type: COMPARATOR
Intervention: Placebo (592 participants)
Number of subjects: 1190

Group type: EXPERIMENTAL
Intervention: Oseltamivir (participants enrolled <48h since symptom onset)
Number of subjects: 1190

Group type: COMPARATOR
Intervention: Placebo (participants enrolled <48h since symptom onset)
Number of subjects: 1190

Group type: EXPERIMENTAL
Intervention: Oseltamivir (all swab specimens, n=1134)
Number of subjects: 1190

Group type: COMPARATOR
Intervention: Placebo (all swab specimens, n=1134)
Number of subjects: 1190

Group type: EXPERIMENTAL
Intervention: Oseltamivir (participants enrolled 48h or longer since illness onset)
Number of subjects: 1190

Group type: COMPARATOR
Intervention: Placebo (participants enrolled 48h or longer since illness onset)
Number of subjects: 1190

Group type: EXPERIMENTAL
Intervention: Oseltamivir (overall)
Number of subjects: 1190
Study: 22634329

Group type: EXPERIMENTAL
Intervention: Gilliatt's pneumatic tourniquet test (supra-systolic pressure)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Gilliatt's pneumatic tourniquet test (infra-systolic pressure)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Gilliatt's test
Number of subjects: 49

Group type: COMPARATOR
Intervention: Phalen test
Number of subjects: 49

Group type: COMPARATOR
Intervention: Durkan test
Number of subjects: 49
Study: 20478960

Group type: EXPERIMENTAL
Intervention: Reliable immunisation camp with small incentives (intervention B); 382 children from 30 villages
Number of subjects: 1640

Group type: EXPERIMENTAL
Intervention: Reliable immunisation camp without incentives (intervention A); 379 children from 30 villages
Number of subjects: 1640

Group type: COMPARATOR
Intervention: Control group (no intervention); 860 children in 74 villages
Number of subjects: 1640